Nanomedicine in Boron Neutron Capture Therapy for Cancer Treatment: Opportunities, Challenges and Future Perspectives
Wei-Jen Chan,Fan-Gang Tseng
DOI: https://doi.org/10.2217/nnm-2021-0082
2021-01-01
Nanomedicine
Abstract:NanomedicineVol. 16, No. 19 EditorialNanomedicine in boron neutron capture therapy for cancer treatment: opportunities, challenges and future perspectivesWei-Jen Chan & Fan-Gang TsengWei-Jen ChanEngineering & System Science, National Tsing Hua University, Hsinchu, 30013, TaiwanSearch for more papers by this author & Fan-Gang Tseng *Author for correspondence: Tel.: +88 603 571 513 134 270; E-mail Address: fangang@ess.nthu.edu.twhttps://orcid.org/0000-0001-7654-6905Engineering & System Science, National Tsing Hua University, Hsinchu, 30013, TaiwanFrontier Research Center on Fundamental & Applied Sciences of Matters, National Tsing Hua University, Hsinchu, 30013, TaiwanResearch Center for Applied Sciences, Academia Sinica, Taipei, 11529, TaiwanSearch for more papers by this authorPublished Online:15 Jul 2021https://doi.org/10.2217/nnm-2021-0082AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: boron neutron capture therapyEPR effectnanomedicinesReferences1. Dymova MA, Taskaev SY, Richter VA, Kuligina EV. Boron neutron capture therapy: current status and future perspectives. Cancer Commun. 40(9), 406–421 (2020).Crossref, Google Scholar2. Franken NA, ten Cate R, Krawczyk PM et al. Comparison of RBE values of high-LET α-particles for the induction of DNA-DSBs, chromosome aberrations and cell reproductive death. Radiat. Oncol. 6, 64 (2011).Crossref, Medline, Google Scholar3. Jing X, Yang F, Shao C et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol. Cancer 18(1), 1–15 (2019).Crossref, Medline, Google Scholar4. Suzuki M. Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era. Int. J. Clin. Oncol. 25(1), 43–50 (2020).Crossref, Medline, Google Scholar5. Hopewell JW, Gorlia T, Pellettieri L, Giusti V, H-Stenstam B, Sköld K. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Appl. Radiat. Isot. 69(12), 1737–1740 (2011).Crossref, Medline, CAS, Google Scholar6. Luderer MJ, De La Puente P, Azab AK. Advancements in tumor targeting strategies for boron neutron capture therapy. Pharm. Res. 32(9), 2824–2836 (2015).Crossref, Medline, CAS, Google Scholar7. Lamba M, Goswami A, Bandyopadhyay A. A periodic development of BPA and BSH based derivatives in boron neutron capture therapy (BNCT). Chem. Comm. 57(7), 827–839 (2021).Crossref, Medline, CAS, Google Scholar8. Malouff TD, Seneviratne DS, Ebner DK et al. Boron neutron capture therapy: a review of clinical applications. Front. Oncol. 11, 351 (2021).Crossref, Google Scholar9. Ichikawa H, Taniguchi E, Fujimoto T, Fukumori Y. Biodistribution of BPA and BSH after single, repeated and simultaneous administrations for neutron-capture therapy of cancer. Appl. Radiat. Isot. 67(7-8), S111–S114 (2009).Crossref, Medline, CAS, Google Scholar10. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268(1), 235–237 (1990).Crossref, Medline, CAS, Google Scholar11. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 21(5), 797–802 (2010).Crossref, Medline, CAS, Google Scholar12. Zhang Q, Liang J, Yun SLJ, Liang K, Yang D, Gu Z. Recent advances in improving tumor-targeted delivery of imaging nanoprobes. Biomater. Sci. 8(15), 4129–4146 (2020).Crossref, Medline, CAS, Google Scholar13. Chan WJ, Cho HL, Goudar V et al. Boron-enriched polyvinyl-alcohol/boric-acid nanoparticles for boron neutron capture therapy. Nanomedicine (Lond.) 16(6), 441–452 (2021).Link, CAS, Google Scholar14. Zhu Y, Lin Y, Zhu YZ, Lu J, Maguire JA, Hosmane NS. Boron drug delivery via encapsulated magnetic nanocomposites: a new approach for BNCT in cancer treatment. J. Nanomater. 2010, 409320 (2010).Crossref, Google Scholar15. Sia J, Szmyd R, Hau E, Gee HE. Molecular mechanisms of radiation-induced cancer cell death: a primer. Front. Cell Dev. Biol. 8, 41 (2020).Crossref, Medline, Google Scholar16. Zhang H, Cheng T, Lai L et al. BN nanospheres functionalized with mesoporous silica for enhancing CpG oligodeoxynucleotide-mediated cancer immunotherapy. Nanoscale 10(30), 14516–14524 (2018).Crossref, Medline, CAS, Google Scholar17. Cioran AM, Musteti AD, Teixidor F et al. Mercaptocarborane-capped gold nanoparticles: electron pools and ion traps with switchable hydrophilicity. J. Am. Chem. Soc. 134(1), 212–221 (2012).Crossref, Medline, CAS, Google Scholar18. Xiong H, Zhou D, Qi Y et al. Doxorubicin-loaded carborane-conjugated polymeric nanoparticles as delivery system for combination cancer therapy. Biomacromolecules 16(12), 3980–3988 (2015).Crossref, Medline, CAS, Google Scholar19. Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J. Control. Rel. 244, 108–121 (2016).Crossref, Medline, CAS, Google Scholar20. Harrington KJ, Mohammadtaghi S, Uster PS et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 7(2), 243–254 (2001).Medline, CAS, Google Scholar21. Moghimi SM, Simberg D. Nanoparticle transport pathways into tumors. J. Nanopart. Res. 20(6), 169–172 (2018).Crossref, Medline, CAS, Google Scholar22. Bürtin F, Mullins CS, Linnebacher M. Mouse models of colorectal cancer: past, present and future perspectives. World J. Gastroenterol. 26(13), 1394 (2020).Crossref, Medline, CAS, Google Scholar23. Mugisho OO, Robilliard LD, Nicholson LF, Graham ES, O'Carroll SJ. Bradykinin receptor-1 activation induces inflammation and increases the permeability of human brain microvascular endothelial cells. Cell Biol. Int. 44(1), 343–351 (2020).Crossref, CAS, Google Scholar24. Tansi FL, Fröbel F, Maduabuchi WO et al. Effect of matrix-modulating enzymes on the cellular uptake of magnetic nanoparticles and on magnetic hyperthermia treatment of pancreatic cancer models in vivo. Nanomaterials 11(2), 438 (2021).Crossref, Medline, CAS, Google Scholar25. Mainetti LE, Rico MJ, Kaufman CD et al. Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models. Oncotarget 11(32), 3048 (2020).Crossref, Medline, Google Scholar26. Chauhan VP, Martin JD, Liu H et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4(1), 2516 (2013).Crossref, Medline, Google Scholar27. Varveris H, Kachris S, Mazonakis M et al. Pegulated liposomal doxorubicin and cisplatin given concurrently with conventional radiotherapy: a Phase I dose-escalation trial for patients with squamous cell carcinoma of head and neck and lung. Oncol. Rep. 12(2), 473–481 (2004).Medline, CAS, Google Scholar28. Liu X, Zhang Y, Wang Y et al. Comprehensive understanding of magnetic hyperthermia for improving antitumor therapeutic efficacy. Theranostics 10(8), 3793 (2020).Crossref, Medline, CAS, Google Scholar29. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 60(16), 4440–4445 (2000).Medline, CAS, Google Scholar30. Kobayashi H, Furusawa A, Rosenberg A, Choyke PL. Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. Int. Immunol. 33(1), 7–15 (2021).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 16, No. 19 Follow us on social media for the latest updates Metrics Downloaded 115 times History Received 1 March 2021 Accepted 28 April 2021 Published online 15 July 2021 Published in print August 2021 Information© 2021 Future Medicine LtdKeywordsboron neutron capture therapyEPR effectnanomedicinesAuthor contributionsWJ Chan and FG Tseng wrote this manuscript. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.Data sharing statementThe authors did not report the original results of a clinical trial or the secondary analysis of clinical trial data.PDF download